Where does The Institute of Cancer Research: Royal Cancer Hospital rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), The Institute of Cancer Research: Royal Cancer Hospital ranks #8,297 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

Is The Institute of Cancer Research: Royal Cancer Hospital's patent grant rate increasing or decreasing?

The Institute of Cancer Research: Royal Cancer Hospital's recent grant velocity is +27% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for The Institute of Cancer Research: Royal Cancer Hospital's patents?

The Institute of Cancer Research: Royal Cancer Hospital's patents average 22.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

The Institute of Cancer Research: Royal Cancer Hospital

Q: How many patents does The Institute of Cancer Research: Royal Cancer Hospital hold?

The Institute of Cancer Research: Royal Cancer Hospital holds 39 US utility patents granted between 2015 and 2025, spanning 20 technology areas.

Q: What is The Institute of Cancer Research: Royal Cancer Hospital's Innovation Score?

The Institute of Cancer Research: Royal Cancer Hospital has an Innovation Score of 51.9 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Q: What technology areas does The Institute of Cancer Research: Royal Cancer Hospital focus on?

The Institute of Cancer Research: Royal Cancer Hospital's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 29 patents, ranking #678 of 6,058 assignees active in that subclass. Grants appear in 20 CPC subclasses total.

Q: How is the The Institute of Cancer Research: Royal Cancer Hospital patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 39 granted patents across 20 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, The ranks #8,297 of 49,997 tracked US assignees by granted-patent volume, with 39 patents across 20 technology areas.

#8,297
of 49,997 US assignees by volume: Top 11%
by Innovation Score (51.9/100): 22.1
avg claims per patent: +27%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8297 · Foreign Corporation #8,297 · 39 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 39 grants
UPPER-Q #8,297/49,997
PHOTO-FINISH Taiwan Union…
CPC-FOCUS A61P · 20 areas
INNOV-PAR 51.9/100
CLAIMS-DENSE 22.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +27% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Taiwan Union Technology Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How The’s 51.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (25%) Velocity 10.0 pts (19%) Breadth 15.8 pts (31%) Claim depth 13.3 pts (26%)

Qualcomm Incorporated · highest

85
Advanced Liquid Logic · near

52
Dispelix OY · near

52
Inje University… · near

52
Medivators · near

52
The Institute of… · this assignee

52
3D Lighting… · lowest

7

What this shows The's Innovation Score is 51.9/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for The?

Each dot is one of The’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). The’s own 22.1 claims/patent is ABOVE the 14.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

The vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where The's grants concentrate

The Institute of Cancer Research: Royal Cancer Hospital is a focused PatentsView assignee: 20 CPC subclasses with 74.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (7 grants) versus a trough of 1 in 2019. By volume, The sits between Toyo Jidoki Co., Ltd. and U.S. Patent Innovations, LLC.

The's three-year grant acceleration

The Institute of Cancer Research: Royal Cancer Hospital shows 12 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Toyo Jidoki

39
Tracer Imaging

39
Taiwan Union Tech…

39
Takeya USA

39
The University of…

39
The Wellboss

39
Toshiba Hokuto

39
U S Patent Innova…

39
The Institute of… ◀

39

What this shows The holds 39 patents at rank #8,300, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near The

By rank, the assignees closest to #8,300 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in The's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for The, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), The ranks #678 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (52 here).

Inje University Industry-academic Cooperation Foundation 52 Dispelix OY 52 Medivators Inc. 52 Advanced Liquid Logic, Inc. 52

The's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

The Institute of Cancer Research: Royal Cancer Hospital patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	10.3%
2016	3	7.7%
2017	7	17.9%
2019	1	2.6%
2020	2	5.1%
2021	5	12.8%
2022	5	12.8%
2023	3	7.7%
2024	4	10.3%
2025partial year	5	12.8%

Which technologies does The Institute of Cancer Research: Royal Cancer Hospital patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 29

C07D - Heterocyclic Compounds 23

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 7

G06T - Image Data Processing OR Generation, IN General 3

C12Y - Enzymes 3

G01R - Measuring Electric VARIABLES; Measuring Magnetic Variables 2

A61B - DIAGNOSIS; SURGERY; Identification 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C07K - Peptides 2

G21K - Techniques FOR Handling Particles OR Ionising Radiation NOT Otherwise Provided FOR; Irradiation DEVICES; Gamma RAY OR X-ray Microscopes 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 2

H01J - Electric Discharge Tubes OR Discharge Lamps 2

C07C - Acyclic OR Carbocyclic Compounds 2

G01S - Radio DIRECTION-FINDING; Radio NAVIGATION; Determining Distance OR Velocity BY USE OF Radio WAVES; Locating OR Presence-detecting BY USE OF THE Reflection OR Reradiation OF Radio WAVES; Analogous Arrangements Using Other Waves 1

Top 15 of 20 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

The Institute of Cancer Research: Royal Cancer Hospital's patent record in context - here's where to go next.

The Institute of Cancer Research: Royal Cancer Hospital's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 74.4% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #8,297 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare The Institute of Cancer Research: Royal Cancer Hospital against Toyo Jidoki Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.